NEW YORK (GenomeWeb News) – Enzo Biochem will seek CLIA waivers for GeneNews' colorectal cancer test in New York and New Jersey and market the test in those states, under an agreement announced by the firms today.
Enzo plans to validate and seek approval in New York, New Jersey, and under CLIA requirements for the ColonSentry blood-based test for colorectal cancer risk. It also intends to market and secure third-party reimbursement for the test. Enzo said it hopes to make the test available in the second half of 2010.
Bernard Levin, chair of the GeneNews' Colorectal Cancer Clinical Advisory Board, said that the test can "encourage individuals to undergo screening which could lead to earlier detection, thereby potentially reducing the suffering and death that can result from this highly treatable disease."
"Enzo is our first US regional marketing partner and will provide an important segment of the eligible US population with access to our ColonSentry test," GeneNews Lead Director and Interim CEO Heiner Dreismann said.